Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...

The narrow FDA labeling makes it so that only a minority of men who could benefit from treatment are considered ‘on-label’ ...

Italian pharmaceutical company Cosmo Pharmaceuticals recently announced that its newly developed male-pattern hair loss ...

Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December ...

Cosmo Pharmaceuticals attracted welcome attention from investors and other market watchers after coming out with topline ...

NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-offNEXGEL will ...

No one wants to think about their cat or dog carrying parasites. But without prevention, the likelihood of infection is high.

Privo Technologies, Inc., today announced that the first patient has been dosed in its first-in-human clinical trial evaluating PRV131 ...

Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics (R) , today announced the close of its $25 million, twice-oversubscribed Series B ...

Confused about which painkiller to use? Pharmacist Meritxell Martí provides a definitive guide on how to take ibuprofen and ...

Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonaltopical ...

Kymera Therapeutics receives US FDA Fast Track Designation for KT-621, an oral STAT6 degrader to treat atopic dermatitis: Watertown, Massachusetts Saturday, December 13, 2025, 18: ...